Who are DICYCLOMINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SOLIFENACIN SUCCINATE, Tolterodine 6, Tolterodine Tartrate ER, Aceclidin, Xanomeline and Trospium Chloride, Tropicamide Ophthalmic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dicyclomine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

DICYCLOMINE — Competitive Intelligence Brief

DICYCLOMINE (DICYCLOMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antispasmodic and anticholinergic (antimuscarinic) agent. Area: Gastroenterology.

marketed Antispasmodic and anticholinergic (antimuscarinic) agent Muscarinic receptors Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

DICYCLOMINE (DICYCLOMINE). Dicyclomine relieves smooth muscle spasm of the gastrointestinal tract via a dual mechanism: anticholinergic effects at acetylcholine receptors and direct smooth muscle relaxation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DICYCLOMINE TARGET	DICYCLOMINE		marketed	Antispasmodic and anticholinergic (antimuscarinic) agent	Muscarinic receptors	1950-01-01
SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE		marketed		Muscarinic receptors	2004-01-01
Tolterodine 6	Tolterodine 6	KYU-SUNG LEE	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors
Tolterodine Tartrate ER	Tolterodine Tartrate ER	University of California, San Francisco	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors
Aceclidin	ACECLIDINE		marketed	aceclidine	muscarinic receptors
Xanomeline and Trospium Chloride	Xanomeline and Trospium Chloride	Collaborative Neuroscience Research, LLC	marketed	Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist	Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism)
Tropicamide Ophthalmic	Tropicamide Ophthalmic	Semnan University of Medical Sciences	phase 3	Anticholinergic	Muscarinic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antispasmodic and anticholinergic (antimuscarinic) agent class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DICYCLOMINE — Competitive Intelligence Brief. https://druglandscape.com/ci/dicyclomine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab